View Item 

Show simple item record

Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A

dc.contributor.authorValentino, L. A.en_US
dc.contributor.authorRecht, M.en_US
dc.contributor.authorDipaola, J.en_US
dc.contributor.authorShapiro, A. D.en_US
dc.contributor.authorPipe, Steven W.en_US
dc.contributor.authorEwing, N.en_US
dc.contributor.authorUrgo, J.en_US
dc.contributor.authorBullock, T.en_US
dc.contributor.authorSimmons, M.en_US
dc.contributor.authorDeguzman, C.en_US
dc.date.accessioned2010-06-01T20:13:00Z
dc.date.available2010-06-01T20:13:00Z
dc.date.issued2009-05en_US
dc.identifier.citationVALENTINO, L. A.; RECHT, M.; DIPAOLA, J.; SHAPIRO, A. D.; PIPE, S. W.; EWING, N.; URGO, J.; BULLOCK, T.; SIMMONS, M.; DEGUZMAN, C. (2009). "Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A." Haemophilia 15(3): 718-726. <http://hdl.handle.net/2027.42/73338>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73338
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19298383&dopt=citationen_US
dc.format.extent169371 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2009 Blackwell Publishing Ltden_US
dc.subject.otherAdvateen_US
dc.subject.otherHaemophilia Aen_US
dc.subject.otherImmune Tolerance Inductionen_US
dc.subject.otherInhibitoren_US
dc.subject.otherThird-generation Recombinant Factor VIIIen_US
dc.titleExperience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia Aen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum¶ Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother* Departments of Pediatrics and Internal Medicine, Rush University Medical Center, Chicago, IL, USAen_US
dc.contributor.affiliationother† Hemophilia Center, Phoenix Children’s Hospital, Phoenix, AZ, USAen_US
dc.contributor.affiliationother† Department of Pediatrics, University of Iowa Children’s Hospital, Iowa City, IA, USAen_US
dc.contributor.affiliationother§ Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USAen_US
dc.contributor.affiliationother** Division of Pediatrics, City of Hope National Medical Center, Duarte, CA, USAen_US
dc.identifier.pmid19298383en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73338/1/j.1365-2516.2008.01960.x.pdf
dc.identifier.doi10.1111/j.1365-2516.2008.01960.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceKasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of Hemophilia. World Federation of Hemophilia: September 2004: no. 34.en_US
dc.identifier.citedreferenceBrackmann HH, Wallny T. Immune tolerance: high-dose regimen In: Rodriguez-Merchan EC, Lee CA eds. “Inhibitors in Patients with Hemophilia”. Oxford, England: Blackwell Science, Ltd, 2002: 45 – 8.en_US
dc.identifier.citedreferenceHay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558 – 63.en_US
dc.identifier.citedreferenceSchwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402 – 6.en_US
dc.identifier.citedreferenceAstermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739 – 45.en_US
dc.identifier.citedreferenceAstermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167 – 72.en_US
dc.identifier.citedreferenceAstermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263 – 5.en_US
dc.identifier.citedreferenceAstermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267 – 72.en_US
dc.identifier.citedreferenceGouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648 – 54.en_US
dc.identifier.citedreferenceKoestenberger M, Raith W, Muntean W. High titre inhibitor after continuous factor VIII administration for surgery in a young infant. Haemophilia 2000; 6: 120.en_US
dc.identifier.citedreferenceGoudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46 – 51.en_US
dc.identifier.citedreferenceSharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228 – 36.en_US
dc.identifier.citedreferenceSantagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422 – 7.en_US
dc.identifier.citedreferenceIngerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 ( Suppl 1 ): 118 – 23.en_US
dc.identifier.citedreferenceLeissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187 – 93.en_US
dc.identifier.citedreferenceLusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179 – 88.en_US
dc.identifier.citedreferenceWhite GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.en_US
dc.identifier.citedreferenceKey NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912 – 8.en_US
dc.identifier.citedreferenceHilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626 – 30.en_US
dc.identifier.citedreferenceArkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255 – 9.en_US
dc.identifier.citedreferenceNegrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113 – 9.en_US
dc.identifier.citedreferenceHo AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547 – 54.en_US
dc.identifier.citedreferenceMariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 ( Suppl 1 ): 25 – 7.en_US
dc.identifier.citedreferenceDiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52 – 7.en_US
dc.identifier.citedreferenceLenk H. The German Registry of immune tolerance treatment in hemophilia--1999 update. Haematologica 2000; 85: 45 – 7.en_US
dc.identifier.citedreferenceBaxter Healthcare Corporation. ADVATE: [package insert]. Westlake Village, CA: Baxter Healthcare Corporation, 2006.en_US
dc.identifier.citedreferenceAstermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363 – 71.en_US
dc.identifier.citedreferenceDiMichele DM, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271 – 3.en_US
dc.identifier.citedreferenceEwing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65 – 8.en_US
dc.identifier.citedreferenceNilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947 – 50.en_US
dc.identifier.citedreferenceDiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280 – 7.en_US
dc.identifier.citedreferenceRothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000; 84: 145 – 6.en_US
dc.identifier.citedreferenceSchwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 1800 – 5.en_US
dc.identifier.citedreferenceBray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428 – 35.en_US
dc.identifier.citedreferenceLusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIIII (BBD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost 1999; 82: 1493.en_US
dc.identifier.citedreferenceEhrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594 – 8.en_US
dc.identifier.citedreferenceIITI. International, Randomised, Controlled Trial of Immune-Tolerance Induction. Available at: http://www.itistudy.com (accessed 12 January 2007).en_US
dc.identifier.citedreferenceKurth MAH, DiMichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50 – 5.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2516.2008.01960.x.pdf
Size:
165.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.